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S U M M A R Y
A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in con-
junction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-
F) to develop evidence-based and consensus-based recommendations for the prevention and treatment
of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/
Willis–Ekbom disease (RLS/WED).
The Task Force made the following prevention and treatment recommendations:
As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial
RLS/WED treatment; these drugs are effective and have little risk of augmentation. Alternatively, if do-
paminergic drugs are elected as initial treatment, then the daily dose should be as low as possible and
not exceed that recommended for RLS/WED treatment. However, the physician should be aware that even
low dose dopaminergics can cause augmentation. Patients with low iron stores should be given appro-
priate iron supplementation. Daily treatment by either medication should start only when symptoms
have a signiﬁcant impact on quality of life in terms of frequency and severity; intermittent treatment
might be considered in intermediate cases.
Treatment of existing augmentation should be initiated, where possible, with the elimination/
correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). In cases of
mild augmentation, dopamine agonist therapy can be continued by dividing or advancing the dose, or in-
creasing the dose if there are breakthroughnight-time symptoms. Alternatively, the patient can be switched
to an α2δ ligand or rotigotine. For severe augmentation the patient can be switched either to an α2δ ligand
or rotigotine, noting that rotigotinemay also produce augmentation at higher doses with long-term use. In
more severe cases of augmentation an opioid may be considered, bypassing α2δ ligands and rotigotine.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Dopaminergic drugs have beenwidely used over the past decades
for the treatment of restless legs syndrome (RLS)/Willis–Ekbom
disease (WED), a neurological sensorimotor disorder character-
ized by an irresistible urge to move the lower limbs especially at
rest, and frequently accompanied by nocturnal dysesthesia.
Two decades ago the major problem with RLS/WED manage-
ment was ensuring that physicians were aware of RLS/WED and able
to identify and therefore treat patients with clinically signiﬁcant
symptoms. The ﬁrst dopaminergic drug to be used for the treat-
ment of RLS/WEDwas levodopa, and while the ﬁrst trials were very
promising, it soon became apparent that the treatment eﬃcacy of
levodopa diminished over time. Of more concern, augmentation, an
iatrogenic and at times profound worsening of RLS/WED symp-
toms following persistent use was recognized [1]. The dopamine
agonists ropinirole, pramipexole, and rotigotine, which have longer
half-lives than levodopa, were approved for the treatment of RLS/
WED between 2004 and 2008 following randomized controlled trials
demonstrating their remarkable short-term eﬃcacy for RLS/WED
symptoms. However, despite the fact that most patients initially
respond very well to dopamine agonists and that this class of drugs
is generally well tolerated over the short-term, longer studies and
clinical experience have demonstrated that treatment eﬃcacy di-
minishes inmany patients over time, and/or augmentation develops,
albeit after a longer duration of treatment than with levodopa [2].
A recent US community-based study estimated that 76% of all pa-
tients treated with dopaminergic agents required either a dose
increase and/or showed indications for partial or full augmenta-
tion, with a yearly incidence rate of approximately 8% [3].
Therefore, today, a major issue with RLS/WED concerns man-
aging treatment over the long-term, and in particular preventing
and treating augmentation, which has become a common and in-
creasing challenge that hinders the successful long-term treatment
of RLS/WED with dopamine agonists.
There are presently no oﬃcial augmentation treatment guide-
lines, and this situation is particularly troublesome for primary care
physicians and specialists without expertise in RLS/WED manage-
ment. Currently, physicians ﬁnd themselves in a situation similar
to the early 1990s, not knowing how to optimally manage RLS/
WED patients over the long-term. For this reason, the International
RLS Study Group (IRLSSG, http://www.irlssg.org) appointed a Task
Force together with the European RLS Study Group (EURLSSG,
http://www.eurlssg.org) and the RLS Foundation (http://www.rls.org)
to review the current evidence and reach a consensus on the pre-
vention and treatment of RLS/WED augmentation.
2. Process and objectives
2.1. Task force
The Executive Committee of the IRLSSG, together with the
EURLSSG and the RLS Foundation, established an international Task
Force to develop recommendations for the prevention and treat-
ment of RLS/WED augmentation. The 13 members of the Task Force
(authors of the current recommendations) include neurologists, psy-
chiatrists, pulmonologists, sleep specialists and pharmacologists from
the USA, Europe and Japan, all with extensive experience in RLS/
WED treatment. All members completed the IRLSSG conﬂict of
interest statement (Appendix 1).
2.2. Objectives
The objectives of the Task Force were (1) to review the evi-
dence on the prevalence, identiﬁcation, prevention, and treatment
of augmentation and, given the paucity of these data, to (2) com-
plement these with consensus-based recommendations of RLS/
WED experts.
3. Methods
3.1. Literature and search strategy
Published papers (meta-analysis, randomized trials, cohort
studies, case–control studies, observational studies) were identi-
ﬁed from the following sources published before 2 October 2014:
Cochrane Database of Systematic Reviews (CSDR) in the Cochrane
Library, Database of Abstract of Reviews of Effects (DARE) in the Co-
chrane Library, CENTRAL (Cochrane Central Register of Controlled
Trial) in the Cochrane Library, National Library of Medicine’s
MEDLINE database, EMBASE database, and CINAHL database. The
electronic databases were consulted using the following search
terms: {[(restless* OR jitter* OR anxiety*) AND (limb* OR leg* OR
tibia*) OR ekbom* OR “restless legs syndrome” OR “willis ekbom
disease”)] AND treat*}.
The search strategy identiﬁed 2718 references (including pos-
sible duplicates). A further search with MeSH terms {(“Restless Legs
Syndrome”[Mesh]) AND (“Clinical Trials as Topic”[Mesh] OR
“Therapeutics”[Mesh])} identiﬁed 538 references (including pos-
sible duplicates).
Inclusion criteria were articles in any language withmean patient
follow-up > 6 months with any assessment of augmentation
(clinical impression, NIH/MPI criteria), as well as any articles which
attempted to identify the characteristics of augmentation (clinical
identiﬁers, neurophysiological predictors). After assessing from title,
abstract or full text of articles, a total of 45 articles for RLS/WED
were eligible for inclusion in the review (Table 1).
3.2. Outcome measures
Table 1 shows the tools that were used to identify and assess
augmentation.
3.3. Data extraction and evaluation of the evidence
Studies were divided into one of the following seven catego-
ries: (1) identifying augmentation, (2) controlled trials with a
duration between six and 12months, and (3) more than 12months,
(4) uncontrolled open-label, case series with a duration between
six and 12 months, and (5) more than 12 months, (6) treatment of
augmentation, and (7) treatment withdrawal.
3.4. Consensus-based clinical recommendations
Consensus was deﬁned by at least 90% of the task force agree-
ing on a clinical recommendation. All task force members agree with
the current recommendations.
3.5. Approval of treatment recommendations
Summaries of both the recommendations were prepared and ﬁrst
presented at the annual meeting of the IRLSSG on March 21, 2015,
in Seoul, South Korea. In addition, an e-mail was sent to all IRLSSG
and EURLSSG members as well as to the Medical Advisory Board
of the RLS Foundation with a copy of the recommendations.
Members were given an opportunity to comment on the recom-
mendations from March 21 to May 11, 2015. The Executive
Committee of the IRLSSG approved the ﬁnal recommendations on
May 12, 2015.
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4. Identifying augmentation
4.1. Augmentation deﬁnition criteria
Augmentation was ﬁrst described and deﬁned in 1996 when it
was reported in 73% of RLS/WED patients treated with carbidopa/
levodopa. The main feature of augmentation identiﬁed in this study
was a worsening of symptom severity manifested by an earlier onset
of symptoms in the afternoon or evening compared with before
treatment initiation, which was severe enough to warrant treat-
ment modiﬁcation in 50% of patients [1]. Other features of
augmentation included a quicker onset of symptoms following rest,
an increased intensity of symptoms, spread of symptoms to differ-
ent body parts, and a shorter duration of the effect of themedication.
Since 1996, several sets of criteria have been established to iden-
tify and evaluate augmentation. In a 2003 NIH-sponsored consensus
conference [4], an operational deﬁnition of augmentation based on
clinical experience was drafted, the primary feature of which was
a drug-induced shifting of symptoms to a period of time 2 h earlier
than was the typical time of daily onset prior to pharmacological
intervention or the worsening of at least two features of RLS/WED
beyond that expected just before or at the onset of treatment.
In 2006 the Max Planck Institute (MPI) criteria established an
operational deﬁnition to assess the severity/clinical signiﬁcance of
augmentation [5]. The main criteria outlined in this deﬁnition were:
a 4-h time advance of symptoms, or a smaller (2- to 4-h) advance
of symptoms together with other required clinical features [5], such
as a shorter latency of symptoms at rest, a spread of symptoms to
other body parts in addition to the lower limbs, or a greater inten-
sity of symptoms. A paradoxical response to treatment – an increase
in severity with increasing dose of medication, and an improve-
ment following decrease in medication – was considered an
alternative key feature for diagnosis.
4.2. Diﬃculties diagnosing augmentation
The existing criteria [4,5] were developed for use in clinical re-
search. Since they require a baseline assessment, they are diﬃcult
to use in everyday clinical practice. Also, these criteria were not de-
signed to identify initial symptoms of augmentation. Furthermore,
the MPI criteria do not seem suﬃciently sensitive to detect aug-
mentationwhenmedications are very long acting (such as rotigotine)
or are given multiple times a day, since these criteria rely heavily
on an anticipation in the time of onset of symptoms.
4.3. Paradoxical response
The complexity of these criteria gives an indication of the dif-
ﬁculties encountered in diagnosing augmentation in daily clinical
practice. First, it is diﬃcult to establish paradoxical response to treat-
ment, which is considered a key diagnostic feature of augmentation:
increasing doses of dopaminergic agents, especially if taken earlier
in the day before RLS/WED onset, often improve symptoms, only
for them to worsen again after some time on the higher dose. Con-
versely, with dose decreasemost patients’ symptoms initially worsen
for several days to weeks due to withdrawal from the drug before
eventually improving. Whereas with levodopa an improvement in
symptom severity can be seen within a few days after discontinu-
ing the drug, with dopamine agonists it can take several weeks to
months for a patient to notice any signiﬁcant improvement, during
which time they must endure severe worsening of symptoms.
4.4. Identifying augmentation
Seven articles were reviewed speciﬁcally with regard to iden-
tifying augmentation [3,6–11].
4.4.1. Clinical identiﬁers of augmentation
Tzonova et al. performed a cross-sectional study among RLS/
WED patients who had been treated with dopaminergic agents for
a mean of six years, 41.3% of whom suffered daily daytime (‘break-
through’) symptoms [11]. This study shows that despite an initial
response to dopaminergic agents, with time, symptoms could no
longer be completely managed, but only 5% of patients met aug-
mentation criteria. The authors suggest that breakthrough crises
could be early signs of augmentation. Beginning augmentation may
be much more frequent in clinical series [3,12] and almost half of
the patients on very-long-term treatment were unchanged or even
worse at the end compared to the beginning of a very-long-term
observational period [13]. The objectives of an observational cross-
sectional community study completed by Allen et al. were to examine
the potential risk factors or predictors of augmentation [3].
Five factors were found to reﬂect a likely increased risk of de-
veloping augmentation: (1) more frequent RLS/WED symptom pre-
treatment, (2) greater discomfort with RLS/WED symptoms before
treatment, (3) comorbid asthma, (4) older age, and (5) longer treat-
ment duration (p < 0.05). A retrospective assessment of augmentation
and tolerance in patients treated with pramipexole reported that
previous tolerance with levodopa increased the probability of
Table 1
Overview of tools used to assess augmentation in RLS/WED trials.
Method Description
Allen Earley criteria [1] First description of RLS/WED: augmentation was characterized as an earlier onset of symptoms in the afternoon, a shorter latency to
onset of symptoms when at rest, a spreading of symptoms to the upper limbs and the trunk, an overall increase in the intensity of
symptoms and a shorter effect of the medication.
NIH criteria [4] Clinical criteria based on consensus.
The primary features of augmentation were identiﬁed as a drug-induced shifting of symptoms to a period of time 2 h earlier than the
typical time of daily onset prior to pharmacological intervention OR increased leg movements, decreased duration of treatment beneﬁt,
spread of the symptoms to other body parts, decreased amount of time that it is possible to stay at rest without symptoms, and
paradoxical response to dose increase.
Max Planck Institute
(MPI) criteria for
diagnosing RLS
augmentation [5]
Criteria developed based on empirical information from clinical studies with levodopa and short-acting dopamine agonists, not longer
duration dopamine agents.
The main criteria outlined in this deﬁnition are a four-hour time advance of symptoms, or a smaller (2- to 4-h) advance of symptoms
expressed along with other required clinical indications, such as a shorter latency of symptoms at rest, a spread of symptoms to other
body parts in addition to the lower limbs, or a greater intensity of symptoms. A paradoxical response to treatment – an increase in
severity with increasing dose of medication, and an improvement following decrease in medication – was considered an alternative key
feature for diagnosis.
The greater emphasis on time shift of symptoms may beneﬁt longer-acting dopamine agonists, and this may explain the lower rate of
augmentation found for these drugs.
Augmentation severity
rating scale (ASRS)
Three items are used to assess the severity of augmentation: earlier onset of symptoms, shorter latency to symptom occurrence at rest,
and spreading to other body parts. Augmentation severity is represented in a total score.
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augmentation (p < 0.05) [14]. Ondo et al. performed a prospective
observational study, and simple logistic regression revealed that a
positive family history of RLS/WED, and fewer clinic visits all in-
creased the probability of augmentation, with lack of any neuropathy
being the strongest predictor (p = 0.05). Two studies have exam-
ined the relation between ferritin levels and RLS/WED risk of
augmentation [6,10]. Trenkwalder et al. performed a retrospective
analysis of pooled data from an earlier study with cabergoline and
levodopa [15]. Mean serum ferritin values were lower at baseline
in thosewho developed augmentation (85 ng/mL) compared to those
without augmentation (112 ng/mL). Frauscher et al. reported an
inverse correlation between serum ferritin levels and RLS/WED aug-
mentation [6].
The task force also consideredwhether RLS/WED severity at base-
line is linked to the likelihood of developing augmentation. It appears
that more severe RLS/WED is a risk factor for augmentation, but this
may result from tendency to use higher doses for more severe
symptoms.
The above studies, while continuing to shed light on augmen-
tation and how it manifests, do not allow the task force to make
recommendations on the identiﬁcation of augmentation in daily
practice. Therefore, a consensus-based recommendation was agreed
upon.
4.4.2. Neurophysiological predictors
Mitterling et al. conducted a prospective study to evaluate the
possibility of establishing polysomnographic markers of augmen-
tation [8]. While video polysomnography found no signiﬁcant
differences in PLM indices between the augmented and non-
augmented groups, an unexpected relatively lowmedian PLM during
sleep (PLMS) index was found in augmented patients. A 60-min sug-
gested immobilization test (SIT) was also performed before every
sleep study and showed that only augmented patients had a sub-
stantial number of PLMs during the test. Augmented patients scored
signiﬁcantly higher on item 4 on the RLS-6 scale, which concerns
RLS/WED daytime symptoms at rest. The authors conclude that aug-
mentation of RLS/WED predominantlymanifests during wakefulness
[8]. Another study [7] also found no association between PLMs and
augmentation. So, while conventional sleep studies do not seem
useful to identify augmentation, immobilization testsmight be prom-
ising, but further research is needed.
4.5. Consensus-based recommendation for the identiﬁcation of
augmentation
To facilitate the identiﬁcation of augmentation in clinical prac-
tice, physicians might wish to consider that augmentation may be
present whenever a patient who has been on stable treatment for
at least 6 months requests more medication. The IRLSSG task force
recommends four screening questions, that have yet to be vali-
dated, that may be used in clinical practice in patients currently
under treatment with dopaminergic agents. An aﬃrmative answer
to any of these four questions should lead the physician to suspect
that augmentation may be present:
1 Do RLS/WED symptoms appear earlier than when the drug was
ﬁrst started?
2 Are higher doses of the drug now needed, or do you need to take
the medicine earlier, to control the RLS/WED symptoms com-
pared to the original effective dose?
3 Has the intensity of symptoms worsened since starting the
medication?
4 Have symptoms spread to other parts of the body (eg, arms) since
starting the medication?
It is important to remember that augmentation may progress
in a ﬂuctuating manner over time. It needs to be differentiated from
multiple augmentation mimics: natural progression of RLS/WED,
ﬂuctuations in disease severity, tolerance, end-of-dose rebound
(Table 2), and worsening due to exacerbating factors. RLS/WED is
thought to progressively worsen over time but unlike augmenta-
tion, symptoms show lasting improvement with increased dose [16].
Tolerance refers to a decrease in medication eﬃcacy over time,
thereby necessitating an increase in dosage in order to maintain the
initial relief of symptoms. In contrast to augmentation, in the case
of tolerance RLS/WED symptoms do not appear earlier in the day,
nor do they become more severe than at baseline. However, data
indicate that tolerance likely precedes or is a subtype of augmen-
tation [14]. End-of-dose rebound occurs in up to 35% of RLS/WED
patients and refers to the reappearance of symptoms in the early
morning, the time at which the medication concentration is falling.
It is therefore more commonwith drugs with a shorter half-life such
as levodopa [17], or less frequent when other dopamine agonists
such as ropinirole or pramipexole are given in the early evening or
afternoon. Similar to augmentation, the symptoms of rebound are
worse than at baseline, but there is no spread of symptoms to the
arms, nor a worsening with increased dose, or conversely no im-
provement with decreased dose. Factors that may exacerbate RLS/
WED symptoms include iron deﬁciency, poor medication adherence,
sleep deprivation, lifestyle changes (eg, more sedentary lifestyle),
appearance of other physiological or pathological conditions known
to trigger or exacerbate RLS/WED (pregnancy, renal insuﬃciency,
other sleep disorders particularly sleep-disordered breathing), and
medications such as antihistamines, dopamine-receptor blockers,
or serotonergic antidepressants [18].
4.6. Prevalence of augmentation with different dopaminergic drugs
To evaluate the frequency of augmentation the task force re-
viewed 28 studies: four controlled trials lasting between 26 and 30
weeks [15,19–21], one controlled trial lasting more than one year
[2], seven uncontrolled studies lasting between 26 and 52 weeks
[1,14,22–26], and 16 uncontrolled studies lasting more than one
year [9,12,27–40].
Table 2
Differential diagnosis of augmentation.
Augmentation End of dose rebound Tolerance Natural progression Exacerbating factors*
Worse than before treatment Yes Yes, in early morning No Yes Yes
Earlier onset Yes Yes, in early morning No Yes Yes
Spread to arms Yes No No Yes Yes
Breakthrough at night Yes Yes, in early morning Yes Yes Yes
Worse with increased dose Yes, but not immediately No No No No
Improved with decreased dose Yes, but not always† No No No No
* For example, low serum ferritin, medications, increased immobility.
† Eventually augmentation is overcome when the dose is decreased; and while augmentation symptoms can improve within 72 h on levodopa, it can take several weeks
to several months to see an improvement with dopamine agonists.
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Augmentation prevalence is diﬃcult to evaluate as it varies ac-
cording to the drug, its dose, the duration and type of study, the
criteria used to evaluate augmentation, and the number of sub-
jects. However, some degree of augmentation has been reportedwith
the use of all investigated dopaminergic drugs as well as for the atyp-
ical opioid tramadol (which has some dopaminergic effect) [41].
However, despitemultiplemethodologies, and different levels of rigor
in assessing augmentation, a clear difference between augmenta-
tion rates and the duration of studies can be seen: for short-term
studies the augmentation rates are <10% [2,20,23,32,33], for studies
lasting two to three years the augmentation rate increases to ap-
proximately 30% [3,9,14,38,39], while two of the three long-term
(approx. 10 years) studies available reported augmentation in 42–
68% of patients [12,36]. Furthermore, one randomized double-
blinded control study showed a signiﬁcant increase in rates of
augmentation on pramipexole for 12 compared to six months on
a ﬁxed dose of pramipexole (either 0.5 or 0.25 mg) [2]. Based on
this evidence, the Task Force concludes with reasonable certainty
that the likelihood of augmentation increases with duration of
treatment.
In the near absence of direct comparative studies for augmen-
tation rates with different dopaminergic medications, the incidence
rate appears to be highest during treatment with levodopa [1] and
is higher for shorter-acting (pramipexole, ropinirole) [32,36,42] than
longer-acting dopamine agonists (cabergoline, rotigotine) [37].
However, as mentioned above, such evidence is far from deﬁnite
and it is unclear whether this ﬁnding is related to masking of earlier
symptom onset by the longer-acting dopaminergic agents or if it
is truly an augmentation-sparing effect. Hence, there is insuﬃ-
cient evidence that longer-acting drugs cause a lower incidence rate
of augmentation.
5. Consensus-based recommendations
Most studies on the treatment of augmentation have a low class
level of evidence. There are no controlled studies and decisions fre-
quently had to be reached based on consensus provided by experts.
Studies that investigated the prevention of augmentation havemany
limitations: these studies were sponsored, run and evaluated by the
industry. Moreover, the deﬁnition of augmentation used in these
studies was frequently very restrictive, and the duration of the studies
was not long enough to see the full scope of augmentation.
5.1. Reducing impact of risk factors
Ten studies were reviewed concerning the treatment of aug-
mentation. These studies were classiﬁed according to previously used
criteria for treatment trials [43]. Two of these studies provide class
IIIc evidence, while the remaining eight studies provide class IV ev-
idence. These studies were generally open label designs that were
insuﬃciently powered and had inadequate endpoints. It is there-
fore impossible to make recommendations on the treatment of
augmentation based exclusively on empirical data.
Nevertheless, the task force agreed that treatment with dopa-
minergic agents poses the greatest risk for augmentation; that
augmentation is likely exclusively related to the speciﬁc action of
the dopaminergic system; and that this risk is strongly correlated
with the dose and duration of treatment [2,3,12,36].
Therefore, the most effective preventive strategy would be to not
use dopaminergic agents. However, should dopaminergic treat-
ment be selected, then it is recommended that the dopaminergic
load be kept low by using the minimum effective dose for the short-
est required period of time. Other factors that are thought to
contribute to an increased risk of augmentation include low iron
stores [6,10]; greater severity of RLS/WED symptoms prior to ini-
tiation of treatment [1,3]; possibly, a family history of RLS or lack
of neuropathy [9].
5.2. First-line treatment of de novo patients
The primary long-term concern with dopaminergic agents is the
development of augmentation. While many short-term effects are
apparent within days or weeks and thus become easy to identify,
augmentation frequently develops gradually and insidiously. Fur-
thermore, its similarity to natural progression of the disease might
make it diﬃcult to detect before it becomes a signiﬁcant problem.
For these reasons, preventive strategies need to be implemented
to minimize, and if possible, avoid the dopaminergic load in every
de novo patient. The physician, particularly if not very experi-
enced in long-term management of RLS/WED, should keep
dopaminergic load as low as possible in previously untreated RLS/
WED patients, and should consider using treatmentmedications that,
while effective, have little or no risk of augmentation for initial RLS/
WED. As the α2δ ligands (Table 3) do not have this long-term risk,
they may be considered for initial RLS/WED treatment. Similarly,
other authors have recommended that treatment be initiated with
α2δ ligands [44].
Before an initial treatment is selected, the long-term risk of aug-
mentation has to be weighed against the short- and intermediate-
term side effects and beneﬁts associated with each treatment option
(see Tables 4 and 5), the patient’s response to previous treatment
for RLS/WED, possible interaction with other treatments, and the
patient’s comorbid conditions and clinical status. It should be noted
that application site reactions to rotigotine transdermal patches are
consistently high in RLW/WED [37].
In addition, the use of non-dopaminergic options as a ﬁrst-line
treatment is limited by the fact that in some regions of the world
(ie, Europe) no such treatments are approved for RLS/WED.
5.2.1. Adjusting daily treatment of RLS/WED to prevent
augmentation
If a patient is already being treated with a dopaminergic agent,
the lowest possible cumulative daily dopaminergic dose should be
used to control the majority of bothersome RLS/WED symptoms,
and the total daily dose should not exceed maximum recom-
mended levels (pramipexole, 0.5–0.75 mg; ropinirole, 4 mg;
rotigotine, 3 mg; Table 6). However, even low-dose dopaminergic
treatments have a risk of augmentation [2]. Physicians should explain
to patients that the goal of treatment is not to completely eradi-
cate symptoms but to ensure they do not interfere with quality of
life. If symptoms become bothersome, the dose can be increased
cautiously, but this will increase the risk of developing augmenta-
tion. A non-dopaminergic agent can be added if concerns about
dose of the dopaminergic drug occur. These therapeutic decisions
should also be based on other factors related to patient character-
istics such as age, previous episodes of augmentation, and
vulnerability to class-related side effects.
Table 3
α2δ ligand suggested doses*.
Starting dose Usual effective
daily dose
<65 years >65 years
α2δ ligands
Approved (USA, Japan as of 2015)
Gabapentin enacarbil 600 mg 300 mg 600–1200 mg
Not approved
Pregabalin 75 mg 50 mg 150–450 mg
Gabapentin* 300 mg 100 mg 900–2400 mg
* Long-term studies have not been performed with gabapentin in RLS/WED and
absorption is variable, thereby complicating dosing.
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5.2.2. Intermittent (non-daily) treatment of RLS/WED to prevent
augmentation
The daily treatment of RLS/WED should be deferred as long as
possible until symptoms occur almost daily. However, a number of
factors make this goal diﬃcult to achieve. First, in patients with in-
termittent RLS/WED the emergence of symptoms is often
unpredictable. Second, many patients ﬁnd that it is more effective
to take medication prior to onset of symptoms, preventing their oc-
currence, rather than waiting until after symptom onset.
Nevertheless, the goal of intermittent dosing should be pursued, es-
pecially if symptoms are infrequent (<1–2 per week), or as preventive
medications before predictable conditions of immobility (eg, long
car or plane trips, medical procedures). Levodopa may be used for
intermittent treatment atmost two to three times aweek, but should
not be used for daily treatment, given the high risk of augmenta-
tion with this medication.
5.2.3. Using longer acting dopamine agonists
As mentioned above, longer-acting dopaminergic agonists may
cause less augmentation than shorter-acting dopamine agonists. As
with all other dopamine agonists, the dose of longer-acting dopa-
mine agonists should never be increased above recommended levels
(rotigotine, 3 mg) for the treatment of RLS/WED.
5.2.4. Fluctuating RLS/WED symptoms
Longitudinal studies demonstrate that RLS/WED symptom in-
tensity ﬂuctuates and that some patients appear to go into
spontaneous remission. Therefore, in patients with a history of
notable ﬂuctuating RLS/WED symptoms, the clinician may consid-
er it appropriate to intermittently attempt to reduce the dose or even
discontinue the drug in order to ensure that the patient is being
treated with the lowest effective dose. If implemented, the patient
should be made aware that withdrawal symptoms may be severe
and may occur for several days or even weeks after dose reduc-
tion and this has to be distinguished from the requirement for
continued medication treatment or a true worsening of RLS/WED
symptoms.
5.2.5. Switching to an alternate dopaminergic agent
Switching from one dopamine agonist to another is generally not
considered useful for preventing (or treating) augmentation, except
for switching from levodopa to a longer-acting formulation of a ap-
proved dopamine agonist. Physicians may wish to consider long-
acting formulations of dopamine agonists as an alternative to reduce
the risk of augmentation, although there is no evidence that this
will ultimately delay or prevent augmentation. Table 7 provides the
suggested initial dose for switching dopamine agonists.
Table 4
Factors that affect selection of an agent for initial treatment in patients with restless legs syndrome/Willis–Ekbom disease (adapted from Garcia-Borreguero et al. [43]).
Factor that impacts the choice of agent Treatment choice
Time of day (daytime symptoms) Preferably a long-acting agent
Twice-a-day dosing of a short-acting agent
Sleep disturbance disproportionate to other symptoms of
RLS/WED, eg, severe insomnia
α2δ ligand
Comorbid insomnia α2δ ligand
Pregnancy risk Avoid both DAs and α2δ ligands
Consider the use of iron
Impaired renal function Select a drug that is not renally excreted or reduce dose of renally excreted drugs
Increased risk of falls Dopamine-receptor agonist
Painful restless legs α2δ ligand
Comorbid pain syndrome α2δ ligand
History of impulse control disorder α2δ ligand
History of alcohol or substance abuse Dopamine-receptor agonist or α2δ ligand
Very severe symptoms of RLS/WED Dopamine-receptor agonist
Excess weight, metabolic syndrome Dopamine-receptor agonist
Availability or cost of drug Dopamine-receptor agonist or α2δ ligand
Comorbid depression Dopamine-receptor agonist
Comorbid generalized anxiety disorder α2δ ligand
Higher potential for drug interactions Select drug that is not hepatically metabolized
Symptomatic PLMS Dopamine-receptor agonist
Table 5
Common adverse at 52 weeks (adapted from Allen et al. [2]).
Event Pregabalin 300 mg Pramipexole 0.25 mg Pramipexole 0.5 mg
Serious adverse events, no. 11 20 12
Patients with serious adverse events, no. (%) 9 (4.9) 12 (6.7) 9 (5.0)
Patients with adverse events, no. (%) 155 (85.2) 142 (79.8) 140 (77.8)
Discontinuations due to adverse events, no. (%) 50 (27.5) 33 (18.5) 43 (23.9)
Suicidal ideation, no. 6 3 2
Common adverse events, no. (%) appearing in >8% of patients
Dizziness 39 (21.4%) 15 (8.4%) 17 (9.4%)
Somnolence 32 (17.6%) 12 (6.7%) 14 (7.8%)
Fatigue 23 (12.6%) 19 (10.7%) 22 (12.2%)
Headache 22 (12.1%) 30 (16.9%) 35 (19.4%)
Nasopharyngitis 19 (10.4%) 20 (11.2%) 17 (9.4%)
Weight gain 16 (8.8%) 12 (6.7%) 12 (6.7%)
Constipation 14 (7.7%) 3 (1.7%) 2 (1.1%)
Nausea 11 (6.0%) 18 (10.1%) 26 (14.4%)
Back pain 10 (5.5%) 16 (9.0%) 13 (7.2%)
Inﬂuenza 9 (4.9%) 13 (7.3%) 3 (1.7%)
Vomiting 3 (1.6%) 4 (2.2%) 10 (5.6%)
Diarrhea 7 (3.8%) 9 (5.1%) 10 (5.6%)
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6. Recommendations
Because a substantial number of patients on dopaminergic treat-
ment will develop augmentation, the physician, particularly if not
very experienced in long-termmanagement of RLS/WED, may con-
sider using for initial RLS/WED treatment medications that, while
effective, have little or no risk of augmentation.
Hence, a treatment trial with α2δ ligands may be considered as
an initial treatment as this class of drugs has been shown in 1-year
studies to have no signiﬁcant risk of augmentation. However, as with
any other treatment, their proﬁle of short- and intermediate-term
side effects should be considered in selecting the most appropri-
ate drug. This recommendation is also limited by lack of availability
or regulatory approval for α2δ ligands in certain regions of the world
(eg, Europe).
Alternatively, if dopaminergic drugs are elected as initial treat-
ment, the daily dose should not exceed that recommended for RLS/
WED treatment. Daily treatment with dopaminergic drugs should
start only when symptoms have a clear impact on quality of life in
terms of frequency and severity; intermittent treatment might be
considered in milder cases.
Patients with low iron stores should be given appropriate iron
supplementation.
7. Treatment of augmentation (Fig. 1, Table 8)
7.1. Elimination of exacerbating factors
The ﬁrst step in treating augmentation consists of the elimina-
tion and/or correction of any exacerbating factors.
The patient’s serum ferritin level should be measured, and, if the
concentration is <50–75 μg/mL, or if transferrin saturation is less
than 20%, supplementation with orally administered iron is rec-
ommended unless poorly tolerated or contraindicated. Intravenous
(IV) iron can also be considered.
It is important to ask the patient about any lifestyle changes (sleep
deprivation, alcohol use, decreased mobility), or changes in medical
factors (use of dopamine antagonists, antihistamines or antide-
pressants, recent opioid discontinuation, blood loss) that can
contribute to an earlier onset or an increase in the severity of RLS/
WED symptoms.
Any extrinsic factors exacerbating RLS/WED expression should
be adjusted as much as possible to reduce the need for RLS/WED
medication changes.
Table 6
Suggested initial dose and maximum recommended dose for dopamine agonists.
Initial dose Max. recommended dose
Pramipexole 0.125 mg/day 0.75 mg/day
Ropinirole 0.25 mg/day 4 mg/day
Rotigotine 1 mg/day 3 mg/day
Table 7
Suggested initial dose for switching dopamine agonists.
Rotigotine Pramipexole ER*
Pramipexole
0.25 mg 2 mg 0.375 mg
0.50 mg (or higher) 3 mg 0.75 mg
Ropinirole
0.5–1.0 mg 2 mg 0.375 mg
2 mg or higher 3 mg 0.75 mg
* The incidence rate of augmentation has not been assessed with pramipexole ex-
tended release.
OR
OR
OR
Mild augmentation (all of the below)
1. Temporal shift 
2. Dopaminergic dose is maximum recommended dose
3. Symptoms cause mild distress
4. There has been no prior increase in dose above what 
was previously therapeutically effective
Severe augmentation
1. Not mild, OR
2. Does not respond to treatment for mild augmentation
Keep the same 
dopamine agonist 
One of the below three
options:
1. Split with same dose;
2. Advance the dose 
earlier.
If options 1 and 2 fail 
3. Consider increasing the 
dose but keeping it at/ 
below approved daily dose
Switch
Switch patient from 
a short-acting 
dopamine agonist to 
rotigotine or a long-
acting dopamine 
agonist if this is not 
already the case.
If this strategy fails 
consider a complete 
switch of medication
The objective is to reduce, & if possible eliminate the short-acting 
dopamine agonist and to begin treatment with rotigotine or a long acting 
or in severe cases a long-acting opiate
Three strategies are available for doing this:Complete switch
to one of the options 
below
OR
Rotigotine or a long-
acting dopamine 
dose 
Augmentation
Eliminate exacerbating factors
(serum ferritin < 50-75 g/mL], lifestyle changes, exacerbating drugs)
If this strategy fails 
consider “severe 
augmentation” options
10-day washout
Cross titration
Add an ligand and 
then gradually reduce 
the dose of the 
dopamine agonist with 
the objective of 
eliminating it altogether, 
understanding that this 
may not be possible in 
all cases
• If these strategies fail or if the patient has severe, round-the-clock 
symptoms, then treatment with low doses of an opioid (long-acting 
oxycodone or methadone) should be considered.
• If serum ferritin < 50-75 g/mL then treatment with intravenous iron,
according to availability, should be strongly considered.
Evaluate if any drug 
treatment is needed. 
If symptoms 
continue, introduce 
an or an 
opioid
Fig. 1. Augmentation treatment algorithm. Copyright ©2015 by the International Restless Legs Syndrome Study Group (IRLSSG). All rights reserved. No part of this ﬁgure
may be reproduced or distributed in any form without the prior written permission by the IRLSSG. For permission requests contact secretary@irlssg.org.
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7.2. Mild augmentation
Augmentation exists along a continuum of severity and is arbi-
trarily considered mild if all of the following are present: symptoms
manifest predominantly as a temporal shift of symptoms to earlier
in the day compared to before starting treatment; dopaminergic
monotherapy is at a total daily dose at or below maximum recom-
mended levels; symptoms cause only mild distress; and there has
been no prior increase in total dose above that which was previ-
ously therapeutically effective.
In cases of mild augmentation, the physician can choose one of
two strategies based on the individual characteristics of the patient
(see Fig. 1).
7.2.1. Continue current dopamine agonist therapy
Continue treatment with the same dopamine agonist accord-
ing to one of three possibilities: (1) As a ﬁrst approach the total dose
should be kept the same, but either divided or the time of the dose
should be advanced to before symptom onset. (2) If dividing or ad-
vancing the dose fails, then an alternative is to increase the dose,
usually adding or increasing the earlier rather than the night-time
dose. If, however, the augmentation distress occurs mostly from
symptoms breaking through at night then the night-time dose could
be increased. Make sure that the maximum recommended dose is
not exceeded and that the patient is carefully monitored for con-
tinued augmentation. Only one total daily dose increase should be
performed. (3) If these dose adjustments fail, a switch to another
medication is recommended.
7.2.2. Complete switch
The physician may consider that the existing augmentation, al-
though not severely distressing, is a harbinger of more severe
augmentation and that it is appropriate to switch drugs earlier rather
than later. It must be considered that addressing the augmenta-
tion problem earlier may make the switch easier and less stressful
for the patient.
The patient can either be switched to: (1) an α2δ ligand
(pregabalin, gabapentin enacarbil and gabapentin1) (Table 3 pro-
vides the α2δ ligand suggested doses); or alternatively, depending
on the patient’s clinical features, (2) to rotigotine (other non-
approved extended release oral dopamine agonists such as the
extended release formulation of pramipexole remains relatively
untested, but could eventually be considered as a second line
option) [7].
For switching to an α2δ ligand, one option is to taper off the do-
paminergic agent with a brief period in which the patient is off all
medications. Alternatively, the non-dopaminergic agent can be added
prior to or during the dopaminergic taper.
1 Long-term studies have not been performed with gabapentin in RLS/WED and
absorption is variable, thereby complicating dosing.
Table 8
Treatment of augmentation: evidence.
Study Drug Design Duration Deﬁnition of
augmentation
No. of
patients
Results Class of
evidence*
Maestri et al.
[7]
Pramipexole
ER
Open, case series Mean follow-up
13 months
MPI 24 Resolution of symptoms IIIc
Godau et al.
[45]
Rotigotine Retrospective, case
series
12 months Clinical 28 Resolution of
augmentation within one
month for 27/28 patients.
Discontinuation rate: 14.3%
IIIc
Silver et al.
[12]
Methadone Open, retrospective,
case series
Up to ten years NIH 76 Resolution of symptoms IIIc
Ondo [46] Methadone Open, retrospective,
case series
23 months (range:
4–44 months)
Clinical: greater
intensity and earlier
onset of symptoms
27 (eight
patients
intolerable
augmentation
when on DAs)
8/8 patients with
augmentation showed a
good response (3–5/5
grade). Eﬃcacy rated as
follows: 5, complete relief
of RLS symptoms and
excellent nocturnal sleep;
4, complete relief but
continued subjective sleep
problems; 3, 75–99%
improvement; 2, 25–74%
improvement; 1, 1–24%
improvement; and 0, no
improvement
IV
Miranda [47] Rotigotine Open, prospective
case series
18 months No adequate deﬁnition 10 Resolution of symptoms IV
Stiasny-Kolster
et al. [48]
Pramipexole
low dose
Open, prospective
case series
1–11 days Patients. did not
respond to levodopa,
no further speciﬁcation
17 Good general response IV
Kurlan [49] Gabapentin,
clonazepam
tramadol
Retrospective, case
series
1–43 weeks NIH 14 Mean time to resolution:
GBP (N = 4): 2.6 w (1–6 w);
Clonazepam (N = 3): 14.9
weeks (1–43 weeks);
Tramadol (N = 3): 22.3
weeks (10–31 weeks)
IV
Winkelmann
et al. [50]
Pergolide Open, prospective Six months Clinical 15 All showed improvement
at mean dose of 0.4 mg
IV
Earley et al.
[51]
Pergolide Open, retrospective
case series
18 months
(1–39 months)
Clinical 26 Response rate 83% (19/
23RLS patients) or (19/26
patients with either RLS
[N = 23] or PLMS [N = 3])
IV
* Classiﬁed according to previously used criteria for treatment trials [43].
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As augmentation or withdrawal may take days to weeks to
resolve, evaluation of the eﬃcacy of the new non-dopamine drug
must wait until after this withdrawal period.
If this strategy fails, then alternative approaches described below
for severe augmentation should be attempted.
7.3. Severe augmentation
Severe augmentation is augmentation that either does not fulﬁll
the criteria for mild augmentation (eg, the total agonist dose exceeds
recommended levels or the symptoms cause more than mild dis-
tress), or does not respond to treatment of mild augmentation as
outlined above.
Initially, one of the following approaches should be selected. It
should be noted that most of these approaches have not been ad-
equately substantiated by published data and are largely based on
the experience of individual centers.
7.3.1. Substitution or cross titration
The patient can be switched either to an α2δ ligand or to
rotigotine. Other long-acting DAs might also need to be investi-
gated in the future. In very severe cases a high-potency opioid should
be considered (see Table 9 for suggested doses), bypassing α2δ
ligands and rotigotine (see below). If the patient is switched to
rotigotine, then the shorter-acting dopamine agonist can be dis-
continued and the rotigotine dose adjusted within approved dosage
ranges. If the α2δ ligand is selected, it should be titrated to an ef-
fective dose (so the patient is temporarily on two RLS/WED
medications). At that point, the dopamine agonist dose should be
gradually reduced, warning the patient that a withdrawal is ex-
pected with temporary worsening of symptoms.
The ultimate objective is to eliminate dopaminergic treatment,
or at the very least ensure the lowest possible dopamine dose so
as to minimize the risk of further augmentation. If the attempt
to eliminate all dopaminergic treatment fails, combination therapy
with a low-dose dopamine agonist and an α2δ ligand can be
maintained.
7.3.2. 10-day washout
The patient is gradually weaned off the dopamine drug, fol-
lowed by a washout period of approximately ten days without any
drugs. At the end of the washout period, a new drug may be in-
troduced. The advantages of the ten-day washout are that it enables
the physician to evaluate both the degree of RLS/WED symptoms
on no medication and the beneﬁts of any new drug treatment. In
occasional cases, no continuing drug treatment is needed and this
would not be known without a period off any treatment. The dis-
advantage is that this often leads to transitory extremely severe RLS/
WED symptoms and profound insomnia during the washout period
that may last four or ﬁve days or longer, and may need the rein-
troduction of low-dose dopamine agonists. Education and counseling
support is essential to help the patient with this process.
7.3.3. Consider an opioid
In patients with severe augmentation, such as symptoms with
almost 24 h duration, a low dose of an opioid (prolonged-release
oxycodone [52] or methadone [12]) can be considered instead of
an α2δ ligand (Table 7). These drugs should also be considered if
the above approaches fail. There are, however, special consider-
ations regarding opioids, and the physician should assess risk of
addiction (family or personal history of alcohol or drug abuse, psy-
chiatric comorbidities), risk of non-medical use, or comorbidmedical
issues (eg, pre-existing severe constipation, sleep apnea, pro-
longed QTc).When patients are chosen appropriately, low-dose opioid
therapy is typically very effective and safe even when used for long-
term therapy (based on considerable clinical experience). Educating
the patient about the demonstrated eﬃcacy and safety of these
medications at the doses used in RLS/WED is essential. If the phy-
sician is uncomfortable prescribing opioids, then they should refer
the patient to a physician experienced in managing RLS/WED.
7.4. Iron therapy
If serum ferritin levels are <50–75 μg/mL or transferrin satura-
tion is less than 20%, then treatment with oral or intravenous iron,
depending on the clinical situation, should be strongly consid-
ered. This can be undertaken in combination with any of the other
options.
8. Research agenda
In the future we should (1) perform comparative controlled long-
term (>10 years) trials using standardized augmentation criteria to
providemore accurate augmentation rates and to determine the per-
centage of patients who will develop augmentation on dopamine
agonist therapy over the very long-term; (2) perform controlled
studies on the optimal management of patients with augmenta-
tion; (3) investigate the pathophysiology of augmentation; and
(4) assess methods to identify augmentation and those at risk of
developing augmentation.
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